Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have given written informed consent.~2. Aged 18 years and over.~3. Confirmed histological diagnosis of squamous cell carcinoma of the tongue.~4. primary tumor, regional nodes, metastasis (TNM) stage T1-2 Nx M0.~5. Eligible for local surgery with curative intent.~6. World Health Organization (WHO) Performance status 0-2.~Exclusion Criteria:~1. Previous oncologic surgery and/or external beam radiation therapy on the tongue and oral floor.~2. Major surgery (Oro-facial) within the past 4 weeks or incompletely healed surgical incisions before starting study therapy.~3. Any unresolved toxicity greater than National Cancer Institute (NCI), Common Terminology Criteria for Adverse Events (CTCAE version 4.03) grade 2 from previous anti-cancer therapy.~4. Pregnancy or nursing (women of child-bearing potential).~5. Patients suffering from psychic disorders that make a comprehensive judgment impossible, such as psychosis, hallucinations and/or depression.~6. Previous enrolment in the present study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Holmium-166 microspheres (Type: EXPERIMENTAL): Single session of 4 intratumoral injections consisting of 0.1-0.3 ml radioactive Holmium-166 microsphere suspension with a total activity 30 Megabecquerel, 7-12 days prior to surgical resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).